Chemaphor Inc. of Ottawa, Ontario, reported today that its new subsidiary, Avivagen Animal Health Inc., has begun commercial operations. Avivagen is now marketing exclusively through the veterinary channel in Canada its Oximunol Chewable Tablets for dogs and its in-licensed VetStem RC regenerative cell treatment for dogs, horses and cats. A dedicated interactive website has also been launched. “We believe it is important to take full advantage of the social media capabilities of online communities, to communicate with and build the all-important, long-term relationships with pet parents and veterinarians,” said Dave Hankinson, CEO of Chemaphor and Avivagen. “At the same time this discussion creates awareness of and buying interest in our novel and innovative products and services. “According, we have appointed a dedicated consumer and marketing communications coordinator, Jennifer Febel, who will be blogging on the website and facilitating discussion with website visitors through services such as Facebook and Twitter, as well as by regular e-mail.” Hankinson invited veterinarians who would like to discuss aspects of the company’s products and services to contact Dr. Isabelle Epshtein-Verzberger, veterinary research scientist, at 902-940-7395 or i.verzberger@avivagen.com. <HOME>
